Jonathan Schwartz
Chief Tech/Sci/R&D Officer chez ROCKET PHARMACEUTICALS, INC.
Fortune : 5 M $ au 31/03/2024
Profil
Jonathan David Schwartz is currently the Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Vice President-Clinical Science at Eli Lilly & Co. and as the Vice President-Clinical Development at Stemline Therapeutics, Inc. from 2014 to 2016.
He also held the position of Associate Professor at The Mount Sinai Medical Center, Inc. and Chief Medical Officer & Head-Clinical Development at Rocket Pharmaceuticals Ltd.
Dr. Schwartz obtained a doctorate degree from Washington University in St. Louis and an undergraduate degree from Brown University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/03/2024 | 172 413 ( 0,19% ) | 5 M $ | 31/03/2024 |
Postes actifs de Jonathan Schwartz
| Sociétés | Poste | Début |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 26/03/2024 |
Anciens postes connus de Jonathan Schwartz
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2016 |
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
The Mount Sinai Medical Center, Inc.
 The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Corporate Officer/Principal | - |
Formation de Jonathan Schwartz
| Washington University in St. Louis | Doctorate Degree |
| Brown University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Health Services |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
